Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 4/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22203014 | 1.00 | MAP1LC3B (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL18910972 | 1.00 | MAP1LC3B (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL19046486 | 1.00 | MAP1LC3B (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL19681322 | 0.98 | SIRT2 (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL19502733 | 0.94 | FAP (0.42) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL21013625 | 0.94 | SIRT5 (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL21943700 | 0.94 | FAP (0.42) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL22138815 | 0.93 | FAP (0.39) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL19708459 | 0.93 | SIRT5 (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL21119089 | 0.93 | FAP (0.43) | MAP1LC3BFAPSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2021-09-09 | — | — | US | disclosed |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | ARS Pharmaceuticals, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2019-11-14 | — | — | US | disclosed |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190153108-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | MAP1LC3B 1942/4885FAP 25/4885SIRT2 4127/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | MAP1LC3B 3900/4885FAP 1971/4885SIRT2 4466/4885 |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | MAP1LC3B 337/4885FAP 3796/4885SIRT2 1129/4885 |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | MAP1LC3B 337/4885FAP 3796/4885SIRT2 1129/4885 |
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | NECTIN4, SIGLEC7, CD2 | MAP1LC3B 1205/4885FAP 3630/4885SIRT2 1985/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | MAP1LC3B 1900/4885FAP 3499/4885SIRT2 3784/4885 |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | MAP1LC3B 1490/4885FAP 3807/4885SIRT2 886/4885 |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | HRH3, H1-3, CD274 | MAP1LC3B 337/4885FAP 3796/4885SIRT2 1129/4885 |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | MAP1LC3B 1490/4885FAP 3807/4885SIRT2 886/4885 |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | MAP1LC3B 1490/4885FAP 3807/4885SIRT2 886/4885 |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | MAP1LC3B 451/4885FAP 4493/4885SIRT2 2594/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | MAP1LC3B 1289/4885FAP 35/4885SIRT2 182/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | MAP1LC3B 955/4885FAP 920/4885SIRT2 1353/4885 |
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | NECTIN4, SIGLEC7, CD2 | MAP1LC3B 1205/4885FAP 3630/4885SIRT2 1985/4885 |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | MAP1LC3B 1490/4885FAP 3807/4885SIRT2 886/4885 |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | MAP1LC3B 1490/4885FAP 3807/4885SIRT2 886/4885 |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | MAP1LC3B 1490/4885FAP 3807/4885SIRT2 886/4885 |
| US-20190153108-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | MAP1LC3B 451/4885FAP 4493/4885SIRT2 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.